KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Palvella Therapeutics (PVLA) Net Margin (2016 - 2024)

Palvella Therapeutics has reported Net Margin over the past 9 years, most recently at 4622.87% for Q3 2022.

  • Quarterly Net Margin fell 415434.0% to 4622.87% in Q3 2022 from the year-ago period, while the trailing twelve-month figure was 213.82% through Sep 2022, up 2967.0% year-over-year, with the annual reading at 145.58% for FY2021, 1012.0% up from the prior year.
  • Net Margin was 4622.87% for Q3 2022 at Palvella Therapeutics, up from 5303.48% in the prior quarter.
  • Over five years, Net Margin peaked at 1.74% in Q2 2018 and troughed at 5303.48% in Q2 2022.
  • The 5-year median for Net Margin is 130.34% (2021), against an average of 796.68%.
  • Year-over-year, Net Margin soared 194254bps in 2019 and then plummeted -479334bps in 2022.
  • A 5-year view of Net Margin shows it stood at 1947.0% in 2018, then skyrocketed by 100bps to 4.46% in 2019, then tumbled by -18202bps to 817.06% in 2020, then soared by 84bps to 130.34% in 2021, then crashed by -3447bps to 4622.87% in 2022.
  • Per Business Quant, the three most recent readings for PVLA's Net Margin are 4622.87% (Q3 2022), 5303.48% (Q2 2022), and 67.89% (Q1 2022).